Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $62.00 USD
Change Today -2.25 / -3.50%
Volume 1.2M
ESPR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Open
$63.83
Previous Close
$64.25
Day High
$66.05
Day Low
$61.82
52 Week High
05/21/15 - $120.96
52 Week Low
08/1/14 - $14.23
Market Cap
1.4B
Average Volume 10 Days
1.6M
EPS TTM
$-2.29
Shares Outstanding
22.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ESPERION THERAPEUTICS INC (ESPR)

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies. The company’s products also comprise 4WF, a synthetic apoA-I therapy for treating patients with acute coronary syndrome has completed Phase 2a clinical studies; and ESP41091, which is in pre-clinical trials for lipid metabolism and body weight reduction. Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.

21 Employees
Last Reported Date: 03/10/15

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $450.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $150.0K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2014.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics, Inc. - Special Call

To discuss Phase 2 Results for ETC-1002 in Patients with Hypercholesterolemia and Hypertension

Esperion Therapeutics, Inc. Announces Positive Top-Line Results from ETC-1002-014

Esperion Therapeutics, Inc. announced positive top-line results from ETC-1002-014, a Phase 2 exploratory study evaluating the safety and efficacy of ETC-1002 (bempedoic acid) in patients with both hypercholesterolemia and hypertension. The six-week study met its primary endpoint of greater LDL-cholesterol lowering from baseline with ETC-1002 as compared to placebo. Patients treated with 180 mg of ETC-1002 achieved a 21% reduction in LDL-cholesterol from baseline (p<0.0001), and a 24% reduction as compared to placebo (p<0.0001), which increased by 3%. The reduction occurred within the first two weeks of initiating therapy and continued throughout the treatment period. The LDL-cholesterol lowering effect of ETC-1002 was statistically significant and clinically meaningful. Consistent with prior studies, ETC-1002 demonstrated statistically significant and clinically meaningful reductions of 25% from baseline, 44% vs placebo (p<0.0001), in high-sensitivity C-reactive protein (hsCRP), an important marker of inflammation in coronary disease. ETC-1002 produced a neutral effect on blood pressure, appeared to be safe and well-tolerated and produced no muscle-related adverse events (AEs). ETC-1002 produced no muscle-related AEs or LFT elevations. There were four reported serious adverse event (SAEs) in the ETC-1002 treatment arm, none of which were drug-related, with two discontinuations. ETC-1002-014 Design: The six-week, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the safety and efficacy of ETC-1002 versus placebo in patients with both hypercholesterolemia and hypertension. Secondary objectives were to characterize the safety and tolerability of ETC-1002 in patients with co-morbid hypertension; assess the effect of ETC-1002 on systolic blood pressure (SBP) and diastolic blood pressure (DBP); assess the effect of ETC-1002 on additional lipid and cardiometabolic risk markers, including hsCRP; and characterize the safety and tolerability of ETC-1002. A total of 143 patients with hypercholesterolemia and hypertension were washed out of any lipid-regulating and blood pressure therapies. Seventy one patients received ETC-1002 180 mg and 72 patients received placebo. ETC-1002-014 Results: ETC-1002-treated patients achieved LDL-cholesterol lowering of 21% at six weeks, compared with an increase of LDL-cholesterol of 3% in the placebo group. Levels of hsCRP were reduced by 25% with ETC-1002, compared with an increase of 20% in the placebo group. ETC-1002 was safe and well tolerated, with no muscle-related AEs or ETC-1002-related SAEs. ETC-1002 Demonstrates Consistent Results: ETC-1002 has demonstrated consistent LDL-cholesterol reduction throughout its Phase 2 development program: Top-line results from ETC-1002-009 (a 12-week, Phase 2b study) demonstrated ETC-1002-treated patients achieved 17 and 24% incremental reductions in LDL-cholesterol at doses of 120 mg and 180 mg, respectively, compared with patients on stable statin therapy alone. These reductions were significantly different from placebo (p=0.0055 and p<0.0001, respectively). Top-line results from ETC-1002-008 (a 12-week, Phase 2b study) met its primary endpoint of greater LDL-cholesterol lowering from baseline with ETC-1002 compared with ezetimibe. In patients who received ETC-1002 as monotherapy, there were 27 and 30% eductions in LDL-cholesterol at doses of 120 mg and 180 mg, respectively. These reductions were significantly different from ezetimibe alone (p=0.0008 and p<0.0001, respectively). In patients who received the combination of 120 mg of ETC-1002 and 10 mg ezetimibe, substantial LDL-cholesterol reductions of 43% were significantly different from ezetimibe alone (p<0.0001). In patients who received the combination of 180 mg of ETC-1002 and 10 mg ezetimibe, substantial LDL-cholesterol reductions of 48% were significantly different from ezetimibe (p<0.0001).

Esperion Therapeutics, Inc. - Analyst/Investor Day

Esperion Therapeutics, Inc. - Analyst/Investor Day

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $62.00 USD -2.25

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies
 

Industry Analysis

ESPR

Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit www.esperion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.